Pharma Mar SA PHMMF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $29.29
- Day Range
- $26.85–26.85
- 52-Week Range
- $26.85–46.26
- Bid/Ask
- $28.25 / $32.90
- Market Cap
- $470.09 Mil
- Volume/Avg
- 220 / 552
Key Statistics
- Price/Earnings (Normalized)
- 102.49
- Price/Sales
- 2.72
- Dividend Yield (Trailing)
- 2.61%
- Dividend Yield (Forward)
- 2.76%
- Total Yield
- 5.75%
Company Profile
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 313
- Website
- http://www.pharmamar.com
Comparables
Valuation
|
Metric
|
PHMMF
|
AELIS
|
GRF
|
|---|---|---|---|
Price/Earnings (Normalized) | 102.49 | — | 35.25 |
Price/Book Value | 2.26 | 9.98 | 0.98 |
Price/Sales | 2.72 | 13.79 | 0.86 |
Price/Cash Flow | 23.16 | — | 9.85 |
Price/Earnings
PHMMF
AELIS
GRF
Financial Strength
|
Metric
|
PHMMF
|
AELIS
|
GRF
|
|---|---|---|---|
Quick Ratio | 2.05 | 2.29 | 0.72 |
Current Ratio | 2.63 | 2.41 | 2.48 |
Interest Coverage | −2.20 | −38.47 | 1.28 |
Quick Ratio
PHMMF
AELIS
GRF
Profitability
|
Metric
|
PHMMF
|
AELIS
|
GRF
|
|---|---|---|---|
Return on Assets (Normalized) | 0.66% | −13.75% | 1.17% |
Return on Equity (Normalized) | 1.15% | −26.44% | 4.22% |
Return on Invested Capital (Normalized) | 0.45% | −31.64% | 3.28% |
Return on Assets
PHMMF
AELIS
GRF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cscfwnpj | Nfgl | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mqylsgch | Fjfnd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rqptxzk | Szvmtmb | $99.5 Bil | |
MRNA
| Moderna Inc | Rkbjtcldy | Dpfss | $38.8 Bil | |
ARGX
| argenx SE ADR | Ylxjwkfs | Dfc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hdvgtzs | Rzpv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qjkdftrmt | Blpwcb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Znyztnww | Hqbrmkl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zzkmpycv | Wjrpcx | $12.5 Bil | |
INCY
| Incyte Corp | Ypldkrv | Btjxnc | $11.6 Bil |